AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21110850 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAPC (24 μg/kg/hour) administered intravenously from 1 hour post injury until the end of the 24‐hour experiment
Number of subjects: 21
Study 21110850 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 21
Study 21110850 — intervention group
Group type: EXPERIMENTAL
Intervention: rhAPC (24 μg/kg/hour)
Number of subjects: 21
Study 18368409 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises for 15 patients for 8 weeks in clinic
Number of subjects: 40
Study 18368409 — intervention group
Group type: COMPARATOR
Intervention: Control group of 25 patients with BJHS
Number of subjects: 40
Study 15599642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) - hylan G-F 20, Synvisc, 3 weekly injections into one or both knees (30 knees)
Number of subjects: 30
Study 15599642 — intervention group
Group type: COMPARATOR
Intervention: Saline, 3 intra-articular injections of 2 ml saline at the same intervals (10 knees)
Number of subjects: 30
Study 12712028 — intervention group
Group type: EXPERIMENTAL
Intervention: On-deflate method
Number of subjects: 75
Study 12712028 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-deflate method
Number of subjects: 75
Study 10985480 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalpha 2b (5 MU sqm/daily)
Number of subjects: 43
Study 10985480 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalpha 2b plus low-dose AraC
Number of subjects: 43
Study 10985480 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalpha/AraC therapy
Number of subjects: 43
Study 8803740 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videotape about PSA testing and treatment uncertainties (N = 184 in study 1, N = 103 in study 2)
Number of subjects: 367
Study 8803740 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videotape (N = 103 in study 2)
Number of subjects: 367
Study 8803740 — intervention group
Group type: COMPARATOR
Intervention: No videotape (N = 93 in study 2)
Number of subjects: 367
Study 8803740 — intervention group
Group type: COMPARATOR
Intervention: Another videotape (N = 185 in study 1)
Number of subjects: 367
Study 1864332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration of the right triceps
Number of subjects: 0
Study 1864332 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration of the right biceps
Number of subjects: 0
Study 1864332 — intervention group
Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 0
Study 6424229 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (05 mg/kg/h) after an initial bolus of 1.5 mg/kg
Number of subjects: 5
Study 6424229 — intervention group
Group type: COMPARATOR
Intervention: Pentagastrin (0.02, 0.2, and 2.0 micrograms/kg/h) alone
Number of subjects: 5
Study 30928275 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous FNB 48 h + PCA
Number of subjects: 135
Study 30928275 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐shot FNB + PCA
Number of subjects: 135
Study 30928275 — intervention group
Group type: COMPARATOR
Intervention: PCA alone
Number of subjects: 135
Study 28865249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose HT (0.5 mg 17β‐estradiol/2.5 mg dydrogesterone)
Number of subjects: 150
Study 28865249 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard HT (1 mg 17β‐estradiol/5 mg dydrogesterone)
Number of subjects: 150
Study 28865249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 25617253 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6 mg per day for days 1-7, flexibly dosed 3, 6, or 9 mg per day from week 2 to end of study)
Number of subjects: 228
Study 25617253 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole (2 mg per day for days 1-2, 5 mg per day for days 3-4, 10 mg per day for days 5-7, flexibly dosed 5, 10, or 15 mg per day from week 2 to end of study)
Number of subjects: 228
Study 25617253 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 228
Study 25617253 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 228
Study 23528553 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 56
Study 23528553 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing prosthesis
Number of subjects: 56
Study 23528553 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 21641274 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis
Number of subjects: 64
Study 21641274 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-guided preemptive therapy
Number of subjects: 64
Study 21641274 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis
Number of subjects: 64
Study 19334654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance with nerve stimulation
Number of subjects: 129
Study 19334654 — intervention group
Group type: COMPARATOR
Intervention: Conventional multiple nerve stimulation
Number of subjects: 129
Study 17425158 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted unfractionated heparin (Heparin-'Biochemie' 25.000 IU/5 ml)
Number of subjects: 30
Study 11807634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g plus gentamicin 5 mg/kg
Number of subjects: 211
Study 11807634 — intervention group
Group type: COMPARATOR
Intervention: Cefepime 2 g t.i.d. plus gentamicin 5 mg/kg q.d.
Number of subjects: 211
Study 11807634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone plus gentamicin
Number of subjects: 211
Study 11807634 — intervention group
Group type: COMPARATOR
Intervention: Cefepime plus gentamicin
Number of subjects: 211
Study 10414691 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression dressing
Number of subjects: 135
Study 10414691 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing (control)
Number of subjects: 135
Study 10414691 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression dressing (MRM patients)
Number of subjects: 135
Study 10414691 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing (MRM patients; control)
Number of subjects: 135
Study 10414691 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression dressing (BCT patients)
Number of subjects: 135
Study 10414691 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing (BCT patients; control)
Number of subjects: 135
Study 7589023 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 4 mg (2 tablets, given 6 h apart)
Number of subjects: 13
Study 7589023 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 16 mg (sustained-release, once daily)
Number of subjects: 13
Study 7589023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1689135 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% permethrin cream
Number of subjects: 467
Study 1689135 — intervention group
Group type: COMPARATOR
Intervention: 1% lindane lotion
Number of subjects: 467
Study 225750 — intervention group
Group type: EXPERIMENTAL
Intervention: MSH/ACTH 4-10 (30 mg)
Number of subjects: 24
Study 225750 — intervention group
Group type: COMPARATOR
Intervention: Diluent control solution
Number of subjects: 24
Study 6578828 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 32
Study 6578828 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 32
Study 31037716 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific interventions at resection with primary anastomosis
Number of subjects: 0
Study 31037716 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29723767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg oral/day)
Number of subjects: 44
Study 29723767 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 44
Study 27371945 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 3978
Study 27371945 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 3978
Study 24480113 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive containing 20mcg of ethinyl estradiol and 3mg of drospirenone
Number of subjects: 69
Study 24480113 — intervention group
Group type: COMPARATOR
Intervention: Non‐hormonal contraceptive methods
Number of subjects: 69
Study 22763473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg per day titrated to 20 mg per day)
Number of subjects: 35
Study 22763473 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg per day titrated to 10 mg per day)
Number of subjects: 35
Study 20571820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 mg twice per week for 8 weeks
Number of subjects: 164
Study 20571820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.25 mg twice per week for 8 weeks
Number of subjects: 164
Study 20571820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.125 mg twice per week for 8 weeks
Number of subjects: 164
Study 20571820 — intervention group
Group type: COMPARATOR
Intervention: No maintenance treatment (Group I)
Number of subjects: 164
Study 17962596 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg pravastatin for 2 weeks followed by 40 mg for 4 weeks
Number of subjects: 16
Study 17962596 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin withdrawal
Number of subjects: 16
Study 17962596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16169304 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid (1 g bid)
Number of subjects: 172
Study 16169304 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (1 g bid) alone
Number of subjects: 172
Study 14501103 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed artificial gravity (short-radius centrifugation)
Number of subjects: 0
Study 10326778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (Nicotrol) 5 mg/day during week 1, 10 mg/day during weeks 2 and 3, 5 mg/day during week 4
Number of subjects: 8
Study 10326778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8
Study 7575754 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated microcapsules (A)
Number of subjects: 9
Study 7575754 — intervention group
Group type: COMPARATOR
Intervention: Rapid-release film-coated tablet (B)
Number of subjects: 9
Study 7575754 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release tablet (C)
Number of subjects: 9
Study 1934003 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 100
Study 1934003 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day
Number of subjects: 100
Study 6972824 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoprocoumon (oral anticoagulation) starting on the seventh postoperative day
Number of subjects: 173
Study 6972824 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (control group)
Number of subjects: 173
Study 31542988 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement (CAE) intervention
Number of subjects: 184
Study 31542988 — intervention group
Group type: COMPARATOR
Intervention: BD-specific educational program (EDU)
Number of subjects: 184
Study 31542988 — intervention group
Group type: EXPERIMENTAL
Intervention: Change over time in TRQ between older and younger participants by treatment arm (CAE and EDU)
Number of subjects: 184
Study 30284015 — intervention group
Group type: EXPERIMENTAL
Intervention: Beacon model of integrated care delivered by GPs with special interests
Number of subjects: 305
Study 30284015 — intervention group
Group type: COMPARATOR
Intervention: Usual care delivered by a hospital outpatient department
Number of subjects: 305
Study 29767694 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum α-carotene levels (per log unit (μg/dL) increase)
Number of subjects: 1228
Study 29767694 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum α-carotene concentrations at or above the US average (2.92 μg/dL)
Number of subjects: 1228
Study 29767694 — intervention group
Group type: COMPARATOR
Intervention: γ-tocopherol concentrations at or above the US average
Number of subjects: 1228
Study 26863227 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion condition (video-viewing attention control task)
Number of subjects: 0
Study 26863227 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 24785401 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270
Study 24785401 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study 22207690 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/day
Number of subjects: 100
Study 22207690 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg/day
Number of subjects: 100
Study 22207690 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low trough imatinib levels (< 1200 ng/mL) and low OCT-1 activity
Number of subjects: 100
Study 19560866 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) for 3 days (N=15)
Number of subjects: 24
Study 19560866 — intervention group
Group type: COMPARATOR
Intervention: 8 hours of sleep per night (N=9)
Number of subjects: 24
Study 18204133 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg HFA‐BDP once daily (o.d.)
Number of subjects: 201
Study 18204133 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg HFA‐BDP twice daily (b.i.d.)
Number of subjects: 201
Study 18204133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 16179873 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m) plus treosulfan (2500 or 3000 mg/m2) in cohort 1
Number of subjects: 33
Study 16179873 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m) plus treosulfan (3500 or 4000 mg/m2) in cohort 2
Number of subjects: 33
Study 16179873 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1 (treosulfan dose <=3000 mg/m2)
Number of subjects: 33
Study 16179873 — intervention group
Group type: COMPARATOR
Intervention: Cohort 2 (treosulfan dose >=3500 mg/m2)
Number of subjects: 33
Study 12114041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fel d 1 peptides (90 microg in increasing divided doses)
Number of subjects: 24
Study 12114041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10220224 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemistry with antibodies recognizing NR1 or NR2A/B subunits
Number of subjects: 0
Study 10220224 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron-microscopic observations
Number of subjects: 0
Study 7787130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate, single IV doses ranging from 0.30 to 0.60 mg kg‐1 on day 1
Number of subjects: 32
Study 7787130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate, multiple IV doses ranging from 0.60 to 1.20 mg kg‐1 d‐1 on days 2-9
Number of subjects: 32
Study 7787130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2191584 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg twice daily for 4 weeks)
Number of subjects: 9
Study 2191584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 381954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCRN) 250 mg once or twice daily
Number of subjects: 14
Study 381954 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 50 mg once or twice daily
Number of subjects: 14
Study 31994703 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel 8 mg
Number of subjects: 345
Study 31994703 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel 16 mg
Number of subjects: 345
Study 31994703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 31994703 — intervention group
Group type: EXPERIMENTAL
Intervention: Selatogrel
Number of subjects: 345
Study 31627901 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus bilateral superficial cervical plexus block (GS; n=23)
Number of subjects: 46
Study 31627901 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA; n=23)
Number of subjects: 46
Study 28686000 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared ray abdominal belt
Number of subjects: 0
Study 28686000 — intervention group
Group type: COMPARATOR
Intervention: Hot packs
Number of subjects: 0
Study 25902768 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced exercise cycling (30% faster than voluntary rate, 3 times per week for 8 weeks)
Number of subjects: 100
Study 25902768 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary exercise cycling (3 times per week for 8 weeks)
Number of subjects: 100
Study 25902768 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 100
Study 23811305 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH-dose steroid (prednisolone 5mg/kg/day, n=44)
Number of subjects: 153
Study 23811305 — intervention group
Group type: COMPARATOR
Intervention: Steroids (LOW-dose and HIGH-dose)
Number of subjects: 153
Study 23811305 — intervention group
Group type: COMPARATOR
Intervention: NO steroid (n=91)
Number of subjects: 153
Study 21269291 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1723
Study 17905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 0.8 mg/m2 with carboplatin
Number of subjects: 21
Study 17905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m2 with carboplatin
Number of subjects: 21
Study 17905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 with carboplatin
Number of subjects: 21
Study 17905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.5 mg/m2 with carboplatin
Number of subjects: 21
Study 17905421 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with bortezomib and carboplatin
Number of subjects: 21
Study 16925896 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18 VLP vaccine
Number of subjects: 2404
Study 16925896 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A control vaccine
Number of subjects: 2404
Study 16925896 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control
Number of subjects: 2404
Study 12933352 — intervention group
Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 18
Study 12933352 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM
Number of subjects: 18
Study 12933352 — intervention group
Group type: EXPERIMENTAL
Intervention: OFF
Number of subjects: 18
Study 11885176 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinses
Number of subjects: 663
Study 11885176 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 663
Study 11885176 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 663
Study 11885176 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 663
Study 8991863 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicated (J) reservoir
Number of subjects: 60
Study 8991863 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruplicated (W) reservoir
Number of subjects: 60
Study 8991863 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller (30 cm) reservoirs
Number of subjects: 60
Study 8991863 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger (40 cm) reservoirs
Number of subjects: 60
Study 1307585 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg twice daily
Number of subjects: 60
Study 1307585 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg once daily
Number of subjects: 60
Study 3976820 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity therapy (n = 7)
Number of subjects: 19
Study 3976820 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal therapy (n = 6)
Number of subjects: 19
Study 3976820 — intervention group
Group type: COMPARATOR
Intervention: Normal milieu therapy (control group, n = 6)
Number of subjects: 19
Study 30978259 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial direct current stimulation) targeting inhibitory control
Number of subjects: 10
Study 30978259 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal dlPFC-tDCS
Number of subjects: 10
Study 30978259 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS on inhibitory control accuracy
Number of subjects: 10
Study 30978259 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS on working memory (WM) speed
Number of subjects: 10
Study 29781385 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin group
Number of subjects: 1656
Study 29781385 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 1656
Study 26103919 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular home visits (treatment group)
Number of subjects: 755
Study 26103919 — intervention group
Group type: COMPARATOR
Intervention: Standard community services (control group)
Number of subjects: 755
Study 24494790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training for 2 weeks (6 days week(-1))
Number of subjects: 21
Study 24494790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training for 4 weeks (3 days week(-1))
Number of subjects: 21
Study 23810357 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on quetiapine XR (300 mg/day)
Number of subjects: 688
Study 23810357 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR monotherapy (300 mg/day)
Number of subjects: 688
Study 23810357 — intervention group
Group type: COMPARATOR
Intervention: Add-on lithium (0.6-1.2 mmol/L)
Number of subjects: 688
Study 23810357 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on quetiapine XR
Number of subjects: 688
Study 21988865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (SOC model consultations)
Number of subjects: 61
Study 21988865 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 61
Study 19019888 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy (8 mg/kg every 4 weeks)
Number of subjects: 143
Study 17073813 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF therapy
Number of subjects: 0